期刊文献+

中、大剂量阿糖胞苷治疗急性髓细胞白血病新进展 被引量:4

原文传递
导出
摘要 阿糖胞苷(Ara-C)是治疗急性白血病最有效的药物之一,可用于初治、缓解后和复发患者的治疗。虽然DA方案柔红霉素加Ara-C是治疗急性髓细胞白血病(AML)的标准方案,Ara-C的标准剂量(SD-A)常为100~200mg/m^2·d,但所用Ara-C的最佳剂量仍有很大分歧。
作者 何学鹏 杨科
机构地区 北京军区总医院
出处 《中国实用内科杂志》 CAS CSCD 1995年第9期554-555,共2页 Chinese Journal of Practical Internal Medicine
  • 相关文献

参考文献1

二级参考文献1

  • 1张之南,血液病诊断及疗效标准,1991年

共引文献7

同被引文献22

  • 1楼方定,周绮,朱军,孟凡义,刘海川,汪月增.急非淋白血病强化治疗过程中的骨髓原幼细胞反跳现象[J].军医进修学院学报,1994,15(2):85-88. 被引量:2
  • 2肖志坚.骨髓增生异常综合征的诊断和治疗认识现况[J].国际输血及血液学杂志,2007,30(1):1-4. 被引量:9
  • 3Oheda M, Hattori K, Kuboniwa H, et al. O-linked sugar chain of human granulncyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity[J]. J Biol Chen, 1990 ,265 : 11432.
  • 4Dong F, pouwel K, Hoefsloot HL, et al. The C-terminal cytoplasmic region of the granulocyte colony-stimulating factor receptor mediates apoptosis in maturation incompetent routine cells[J]. Exp Hematol, 1996,24:214.
  • 5Tsuruta T, Tani K, Shimane M, et al. Effects of myrloid cell groath factors on alkakine phosphatase, myrloperixidase, defensin and granuloeyte cotonystimulating factor receptor mRNA expression in haemopoietic cells of normal individuals and myeloid disorders[J]. Br J Haematol, 1996,92:9.
  • 6Santini V,Colomat PH, Delwel R,et al. Induction of granulocyte maturation in acute myeloid leukemia by G-CSF and retinoic aeid. Leukemia[J]. Res,1991,15:341.
  • 7Bin H,Kozo Y. Effects of colony-stimulating factors on neutrophil apoptosis:possible roles at inflammation site[J]. Int J Hematol, 1997,66 : 179.
  • 8Bai A,Kojima H, Hori M,et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apotosis in myeloid leukemia cells[J]. Exp Hematol,1999,27(2) ;259-265.
  • 9Reuter C, Schleyer E, Rolf C, et al. Differential effect of GMCSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts[J]. Leukemia, 1997,11 : 561-571.
  • 10Saito K, Nakamura Y, Aoyagi Y, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor(CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML) and previously untreated elderly patients with AML, secondary AML,and refractory anemia with excess blasts in transformation[J]. Int J Hematol,2000,71 (3):238-244.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部